Our portfolio company Assurex Health just announced the creation of a partnership with Canada’s Center for Addiction and Mental Health (CAMH), one of the world’s leading research centers in the area of addiction and mental health and Canada’s largest mental health teaching hospital. CAMH will offer to Canadian citizens the firm’s pharmacogenomic test, GeneSight, which is now widely available in the US. Claremont Creek Ventures is very excited about this step . . .
→ Read full post: Assurex Health Launches Collaboration with Canadian Mental Health Center
Our portfolio company NuMedii just announced a groundbreaking collaboration with Thomson Reuters, the world’s leading information provider for businesses. The Thomson Reuters Science division has quietly been aggregating an enormous database of biological, clinical, and pharmacological information over the past few years. As a biotech startup, NuMedii is focused on revolutionizing drug discovery by reducing the incredible inefficiencies and costs involved in small molecule drug development.
The drug development process is . . .
→ Read full post: Thomson Reuters and NuMedii Launch Initiative for Drug Discovery
Our portfolio company Assurex Health, announced recently the publication of a groundbreaking analysis of pharmacogenomic data in the International Review of Psychiatry.
The publication strongly validates the premise that the clinical use of genomic testing to help predict patient response to psychiatric medications significantly improves treatment outcomes. This is a key milestone in the continuing discussions within the Psychiatric community about the value of laboratory testing in . . .
→ Read full post: Assurex Health Publishes Seminal Paper on Pharmacogenomics
Our portfolio company Genalyte just announced the award of a government grant from the National Cancer Institute for the development of a diagnostic system using Genalyte’s proprietary biomarker technology (see Genalyte Expands into Cancer Profiling with $1 Million NCI Grant to Develop Cancer Biomarker Panel). This project is a significant validation of the company’s capability to assay blood biomarkers using the multiplex Maverick detection platform, which provides rapid, accurate, . . .
→ Read full post: Genalyte Receives National Cancer Institute Grant
Earlier this week one of our portfolio companies, Genalyte, Inc., announced the release of a groundbreaking diagnostic system for early detection of Type 1 diabetes. This is of special significance to me as the young daughter of a good friend almost died due to undiagnosed Type 1 Diabetes – she was discovered by her parents in a low blood sugar coma in the middle of the night and rushed to . . .
→ Read full post: Genalyte and Colorado Diabetes Center Collaborate on Type 1 Diabetes
Thursday June 20, 2013, Atul Butte, MD, PhD, a Stanford University Professor and entrepreneur is being honored at a formal ceremony in the White House Rose Garden in Washington DC. The Obama Administration is honoring Dr. Butte and several other genomics and molecular biology researchers who have focused on making large and complex sets of biological data open and widely accessible to the larger research community. Butte has been a leader . . .
→ Read full post: NuMedii Founder Atul Butte, MD, PhD honored at White House; Claremont Creek Ventures continues investment in health care Big Data.
Bloomberg reporter Ryan Flinn recently wrote an article on Brain Scans Seek Best Drug Match for Depression Patients. The article summarizes some of the technologies that are being used by clinicians to assist in diagnosis and treatment of depression, and focused on technologies provided by two companies. The first company profiled uses a technology that matches EEGs – brain waves – to a database of matched EEG/depression scores, and the second uses a . . .
→ Read full post: AssureRx: advanced genomics tools inform patient response to psychotropic therapy
I’m excited that we have recently added a new portfolio company Genalyte to the Claremont Creek digital healthcare family. I’ll be joining the Board, and I am looking forward to working with founder and CEO Cary Gunn and the Genalyte team. Genalyte is a developer and manufacturer of advanced biomarker detection technology strategically located right in the center of the San Diego life science community. Claremont Creek Ventures participated in a $11.8 . . .
→ Read full post: My newest investment: Genalyte — Augmenting Claremont Creek Ventures’ Digital Healthcare Tools Portfolio
It is always great to brag and cheer about one of our portfolio companies. Working with portfolio companies to help them succeed is one of a VC’s key jobs, and helping build an executive team is an area where a VC can help a lot. We are pleased to announce that AssureRx Health has just added some super people to its team. The three executives are: Dr. C. Anthony Altar, PhD, chief science officer; . . .
→ Read full post: Claremont Creek Ventures portfolio company AssureRx Health expands senior management team
July 1, 2011 source: Genetic Engineering & Biotechnology News by Brad Webb
Rapid Transition from Laboratory Discoveries to Commercialization Is Transforming Healthcare
It’s been less than a decade since a full human genome was sequenced, but already there is talk that the promise of genomics-inspired personal medicine is not being realized. I couldn’t disagree more. As we point out in this article, cardiologists, psychiatrists, and internists can now order quick and inexpensive genetics-based screening . . .
→ Read full post: Moving Quickly from an Idea to a Product